BC049730 Inhibitors
Chemical inhibitors of Ly6/PLAUR domain containing 10 act through various molecular mechanisms to modulate the activity of this protein, which is implicated in cellular processes such as proteolysis, cell adhesion, migration, and angiogenesis due to its homology with the urokinase plasminogen activator receptor (uPAR). Suramin, for instance, targets growth factors that interact with uPAR, thus hindering the proteolytic activities connected to Ly6/PLAUR domain containing 10. Similarly, Amiloride exerts its influence by inhibiting the urokinase-type plasminogen activator (uPA), which associates with uPAR, consequently affecting the proteolytic cascade involving Ly6/PLAUR domain containing 10. Cilengitide disrupts integrin-mediated cell adhesion, a process where Ly6/PLAUR domain containing 10 is implicated, therefore indirectly reducing its activity. Tyrosine kinase inhibitors like Geftinib and Erlotinib, which target the epidermal growth factor receptor (EGFR), may lead to downstream effects that diminish the functions of Ly6/PLAUR domain containing 10 in cell proliferation and migration.
Continuing with the theme of tyrosine kinase inhibition, Sunitinib and Axitinib obstruct pathways like the platelet-derived growth factor receptors (PDGFR) and vascular endothelial growth factor receptors (VEGFR), which are involved in angiogenesis, a process where Ly6/PLAUR domain containing 10 could also be active. Dasatinib, which inhibits multiple kinases including Src, might lead to decreased Ly6/PLAUR domain containing 10-mediated cell migration and invasion due to the role Src plays in these processes. Moreover, Crizotinib and Bosutinib, targeting anaplastic lymphoma kinase (ALK), ROS1, and c-Met/HGFR, can similarly affect the activity of Ly6/PLAUR domain containing 10 in cell migration. Lastly, Pazopanib, a multi-targeted receptor tyrosine kinase inhibitor, and Vandetanib, which inhibits RET-tyrosine kinase in addition to VEGFR and EGFR, can lead to a decrease in Ly6/PLAUR domain containing 10 activity in related cellular processes due to their broad-spectrum inhibition of kinases involved in cell proliferation and angiogenesis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin inhibits various growth factors and has been shown to inhibit urokinase plasminogen activator receptor (uPAR) which is implicated in the same pathways as Ly6/PLAUR domain containing 10. By inhibiting uPAR, Suramin would lead to the reduction of proteolytic activity associated with Ly6/PLAUR domain containing 10. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride is a known inhibitor of urokinase-type plasminogen activator (uPA), which interacts with uPAR. Since Ly6/PLAUR domain containing 10 is related to the uPAR pathway, inhibition of uPA by Amiloride would inhibit the proteolytic cascade involving Ly6/PLAUR domain containing 10. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Cilengitide inhibits integrins which are involved in cell adhesion, a process that Ly6/PLAUR domain containing 10 is implicated in due to its homology to uPAR. Inhibition of integrins by Cilengitide would therefore inhibit Ly6/PLAUR domain containing 10-mediated cell adhesion processes. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Geftinib is an EGFR tyrosine kinase inhibitor. Since EGFR signaling can be linked with uPAR function and Ly6/PLAUR domain containing 10 is related to uPAR, inhibition of EGFR by Geftinib can result in decreased activity of Ly6/PLAUR domain containing 10. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, similarly to Geftinib, is an inhibitor of EGFR tyrosine kinase. By inhibiting EGFR, Erlotinib would indirectly inhibit downstream effects on cellular processes such as cell migration and invasion where Ly6/PLAUR domain containing 10 may be involved. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that targets pathways including PDGFR and VEGFR. Inhibition of these pathways can decrease angiogenesis and metastasis where Ly6/PLAUR domain containing 10 could play a role due to its association with uPAR-related processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is an inhibitor of multiple tyrosine kinases including Src. Src kinase is involved in cell adhesion, migration, and invasion, where Ly6/PLAUR domain containing 10 is implicated; thus, inhibition by Dasatinib would decrease Ly6/PLAUR domain containing 10 activity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor, including VEGFR, PDGFR, and c-Kit. By inhibiting these pathways, Pazopanib would indirectly inhibit processes such as angiogenesis and cell migration where Ly6/PLAUR domain containing 10 may be active. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits RET-tyrosine kinase, VEGFR, and EGFR, pathways that are involved in cell proliferation and angiogenesis. Inhibition of these pathways by Vandetanib could lead to decreased activity of Ly6/PLAUR domain containing 10 in related cellular processes. | ||||||